Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Safety and Efficacy of Intravenous LY2127399 in Patients With Rheumatoid Arthritis Treated With Methotrexate

NCT00308282 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00308282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00308282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Safety and Efficacy of Intravenous LY2127399 in Patients With Rheumatoid Arthritis Treated With Methotrexate
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
March 28, 2006
Completion date
October 18, 2007
Enrollment
136 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid